Bismuth revisited: An effective way to prevent travelers' diarrhea

Journal of Travel Medicine

Volumn 11, Issue 4, 2004, Pages 239-242

  Rao, Goutham ^a,b   Aliwalas, Martha G ^a   Slaymaker, Elizabeth ^a   Brown, Beverley ^a  

^a St Margaret Memorial Hospital   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISMUTH; BISMUTH SALICYLATE; PLACEBO;

ATAXIA; CLINICAL TRIAL; DISORIENTATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; HUMAN; LOW DRUG DOSE; MENTAL DISEASE; MOTOR DYSFUNCTION; MUCOSA DISCOLORATION; NEUROTOXICITY; NONHUMAN; PIGMENT DISORDER; REVIEW; SEIZURE; SKIN DISCOLORATION; SLEEP DISORDER; SYSTEMATIC REVIEW; TRAVELLER DIARRHEA;

EID: 4043069172     PISSN: 11951982     EISSN: None     Source Type: Journal    
DOI: 10.2310/7060.2004.19008     Document Type: Review

References (27)

1. World Health Organization. The World Health Report 1996: Report of the Director General. Geneva: WHO, 1996:215-219.
2. DuPont HL, Ericsson CD. Prevention and treatment of traveler's diarrhea. N Engl J Med 1993; 328:1821-1827.
3. Kollartisch H. Travelers' diarrhea in Austrian tourists in warm climate countries. Eur J Epidemiol 1989; 5:74-81.
4. Pitzinger B, Steffen R, Tschopp A. Incidence and clinical features of travelers' diarrhea in infants and children. Pediatr Infect Dis J 1991; 10:719-723.
5. Peltola H, Gorbach SL. Travelers' diarrhea: epidemiology and clinical aspects. In: DuPont HL, Steffen R, eds. Textbook of travel medicine and health. Hamilton: BC Decker, 1997:151-159.
6. Blaser MJ. Environmental interventions for the prevention of travelers' diarrhea. Rev Infect Dis 1986; 8(Suppl 2):S142-S150.
7. Reid G, Jass J, Sebulsky MT, McCormick JK. Potential uses of probiotics in clinical practice. Clin Microbiol Rev 2003; 16(4):658-672.
8. Rendi-Wagner P, Kollaritsch H. Drug prophylaxis for travelers' diarrhea. Clin Infect Dis 2002; 34:628-633.
9. Hoge CW, Gambet JM, Srijan A, et al. Trends in antibiotic resistance among diarrhea pathogens isolated in Thailand over 15 years. Clin Infect Dis 1998; 26:341-345.
10. Cheong HJ, Yoo CW, Sohn JW, et al. Bacteremia due to quinolone-resistant Escherichia coli in a teaching hospital in South Korea. Clin Infect Dis 2001; 33:48-53.
11. Stahlmann R, Lode H. Toxicity of quinolones. Drugs 1999; 58(Suppl 2):37-42.
12. Cipro. Drugstore.com. Available at: http://www.drugstore.com/pharmacy/ prices/drugprice.asp?ndc=00026851351&trx=1Z5006 (accessed 20 November 2003).
13. Centers for Disease Control. Travelers' diarrhea. Available at: http://www.cdc.gov/travel/diarrhea.htm (accessed 20 November 2003).
14. AARP Pharmacy Services. Available at: http://www.aarppharmacy.com/ AARPnet/hlp/hlpItemList.aspx?PK=WEBCLASSCBFF&MI=WEBCLASSFB (accessed 20 November 2003).
15. Center for Health Evidence. How to use an article about therapy or prevention. Available at: http://www.cche.net/users-guides/therapy.asp (accessed 20 November 2003).
16. DuPont HL, Sullivan P, Evans DG, et al. Prevention of travelers' diarrhea. Prophylactic administration of subsalicylate bismuth. JAMA 1980; 243:237-241.
17. Graham DY, Estes MK, Gentry LO. Double-blind comparison of bismuth subsalicylate and placebo in the prevention and treatment of enterotoxigenic Escherichia coli-induced diarrhea in volunteers. Gastroenterology 1983; 85:1017-1022.
18. Steffen R, DuPont HL, Heusser R, et al. Prevention of travelers' diarrhea by the tablet form of bismuth subsalicylate. Antimicrob Agents Chemother 1986; 29(4):625-627.
19. DuPont HL, Ericsson CD, Johnson PC, et al. Prevention of travelers' diarrhea by the tablet formulation of bismuth subsalicylate. JAMA 1987; 257(10):1347-1350.
20. Brunton L. Agents for control of gastric acidity and treatment of peptic ulcers. In: Hardman JG, Limbird LE, Molinoff PB, et al., eds. Goodman and Gilman's pharmacological basis of therapeutics, 9th edn. New York: McGraw-Hill, 1996:910.
21. Sarikaya M, Sevinc A, Ulu R, et al. Bismuth subcitrate nephrotoxicity. A reversible cause of acute oliguric renal failure. Nephron 2002; 90(4):501-502.
22. Islek I, Uysal S, Gok F, et al. Reversible nephrotoxicity after overdose of colloidal bismuth subcitrate. Pediatr Nephrol 2001; 16:510-514.
23. Buge A, Rancurel G, Poisson M, et al. Etude neuropathologique et toxicologique de douze cas d'endephalopathies bismuthiques aigues. Rev Neurol 1974; 133:153-163.
24. Lowe DJ. Adverse effects of bismuth subgallate. A further report from the Australian Drug Evaluation Committee. Med J Aust 1974; 2(18):664-666.
25. Nwokolo CU, Fitzpatrick JD, Paul R, et al. Lack of evidence of neurotoxicity following eight weeks of treatment with tripotassium dicitrato bismuthate. Aliment Pharmacol Ther 1994; 8:45-53.
26. Noach LA, Eekhof JLA, Bour LJ, et al. Bismuth salts and neurotoxicity: a randomized single-blind and controlled study. Human Exp Toxicol 1995; 14:349-355.
27. Bradley B, Singleton M, Li Wan Po A. Bismuth toxicity - a reassessment. J Clin Pharm Ther 1989; 14:423-441.